Cancer related fatigue. Drugs, medicaments and biological substances causing adverse effects in therapeutic use
Conditions
Interventions
Intervention 1: Intervention group: administration of bupropion (made by Abidi pharmaceuticals) 75 mg once a day (for three days) then 75 mg twice a day till the end of study (six weeks). Intervention
Sponsors
Mazandaran University of Medical Scienses
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients suffering from cancer-related fatigue Score of at least 4 based on BFI (Brief Fatigue Inventory) scale (0-10) Fatigue with unknown reason for at least one week and more
Exclusion criteria
Exclusion criteria: Age under 18 History of use of the CNS stimulants and antidepressants History of seizure History of use of erythropoietin in the last six weeks. History of suicide Use of MAOIs (Mono Amino Oxidase Inhibitors) in the last two weeks Liver and renal failure Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue score based on BFI scale. Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: BFI questionnaire.;Fatigue score based on Functional Assessment of Chronic Illness Therapy (FACIT). Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: FACIT questionnaire.;Degree of depression an anxiety based on Hospital Anxiety and Depression scale (HADS). Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: HADS questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Performance status based on Eastern Cooperative Oncology Group (ECOG). Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: ECOG questionnaire.;Performance status based on Karnofsky Performance Status Scale. Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: Karnofsky questionnaire.;Patient's quality of life based on European Organisation for Research and Treatment of Cancer QLQ-C30. Timepoint: Before intervention and 2 and 6 weeks after intervention. Method of measurement: EORTC QLQ-C30 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahim Salehifar
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences
Outcome results
None listed